TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06712654: A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

Sponsor: R1 Therapeutics · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 168 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,556,400

Rescue Site Savings

+$1,693,200

Unlock Full NCT06712654 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06712654 Rescue Dossier →